ASCO - malecare.org

Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *

Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]

By Malecare|2014-08-05T14:08:36-04:00August 5th, 2014|Advanced Prostate Cancer, ASCO, bisphosphonates, Chemo Therapy, Chemo Therapy Failure, Combination Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zometa|0 Comments

TAK-700 Fails to Offer A Survival Extension

Much of my reporting about ASCO 2014 has included only positive studies, but there is always a share of studies and trials that do not prove to be of a direct positive value to men with Advanced Prostate Cancer. Today’s report includes one of these negative reports. Remember, a negative report is as valuable as [...]

By Malecare|2021-02-17T11:03:12-05:00June 9th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700, Uncategorized|1 Comment

ASCO 2014 – Exercise Cuts Cytokines in Prostate Cancer

Research released at the ASCO meeting in Chicago confirms that regular exercise is a must for men with advanced prostate cancer. It was found that a regular and structured physical exercise program reduces cytokine production which is related to depression and to the inflammatory processes. According to the researchers these factors may impact prostate cancer [...]

By Malecare|2017-10-19T10:48:09-04:00June 6th, 2014|Advanced Prostate Cancer, ASCO, Drugs & Treatments, General Information, Quality of Life, Research, Uncategorized, Understanding APC|0 Comments

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]

By Malecare|2017-10-19T10:48:10-04:00June 5th, 2014|2nd line hormone therapy, abiraterone acetate, ADT, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi, Zytiga|1 Comment

ASCO 2014 – ADT May Be Deferred After A Bio-Chemical (PSA only) Relapse in Men with Prostate Cancer

Current practice has been to immediately begin hormone therapy (ADT) as soon as a man has a bio-chemical (PSA only) relapse. A recent presentation at ASCO 2014 has shown that immediate ADT actually offers little or no survival benefit over deferred ADT to advanced prostate cancer survivors who experience a PSA only relapse after radical [...]

By Malecare|2014-06-04T10:16:56-04:00June 4th, 2014|ADT, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Drugs & Treatments, PSA, Research, Uncategorized, Understanding APC|0 Comments